Baseline characteristics of the 40 enrolled patients
| Patient characteristics (n = 40) | |
| Gender (female/male), n (%) | 12/28 (32%/68%) |
| Age (y), Median (range) | 48 (28–73) |
| Disease, n (%) | |
| Myeloproliferative disorders: CML/MF/MDS | 3/1/1 (12%) |
| MM | 8 (20%) |
| Lymphoproliferative disorders: NHL/HD/CLL | 5/2/0 (18%) |
| Others: solid tumor | 1 (2%) |
| Transplant, n (%) | |
| MUD | 8 (20%) |
| HLA identical sibling | 32 (80%) |
| PBSC | 30 (75%) |
| BM | 10 (25%) |
| Conditioning regimen, including TBI | 17 (44%) |
| cGVHD | |
| Duration (mo), median (range) | 26 (3–148) |
| Risk score27 (high/intermediate/low), n | 24/15/1 |
| First-line therapy, n | |
| Prednisone (alone or with other drugs) | 36 |
| Miscellaneous (including MMF, tacrolimus, ECP, CSA) | 4 |
| Second and successive lines of therapy, n | |
| Rituximab + miscellaneous (no ECP) | 5 |
| Rituximab + ECP ± miscellaneous | 8 |
| Miscellaneous, including ECP (no rituximab) | 8 |
| Miscellaneous, excluding ECP and rituximab | 19 |
| Karnofsky performance status at enrollment, n (%) | |
| <70 | 28 (70%) |
| 80 | 9 (22%) |
| 90–100 | 3 (8%) |
| Platelet count before imatinib initiation, 109/L, n (%) | |
| <100 | 2 (5%) |
| >100 | 38 (95%) |
| Main cGVHD targets (different organ involvements are not mutually exclusive) | |
| Skin, n (%) | 32 (80%) |
| Mean affected BSA% for erythematous/moveable/nonmoveable sclerosis | 19/27/27 |
| Lung, n (%) | 33 (82.5%) |
| Median values of FEV1/DLCO | 61/55 |
| Mouth, n (%) | 23 (57.5%) |
| Median Schubert Scale value | 3 |
| Liver, n (%) | 6 (15%) |
| Median values of ALT (U/L)/total bilirubin (mg/dL) | 74/3.0 |
| Gut, n (%) | 9 (22.5%) |
| Mean value of the GI scale (0-3) | 1.5 |
| Patient characteristics (n = 40) | |
| Gender (female/male), n (%) | 12/28 (32%/68%) |
| Age (y), Median (range) | 48 (28–73) |
| Disease, n (%) | |
| Myeloproliferative disorders: CML/MF/MDS | 3/1/1 (12%) |
| MM | 8 (20%) |
| Lymphoproliferative disorders: NHL/HD/CLL | 5/2/0 (18%) |
| Others: solid tumor | 1 (2%) |
| Transplant, n (%) | |
| MUD | 8 (20%) |
| HLA identical sibling | 32 (80%) |
| PBSC | 30 (75%) |
| BM | 10 (25%) |
| Conditioning regimen, including TBI | 17 (44%) |
| cGVHD | |
| Duration (mo), median (range) | 26 (3–148) |
| Risk score27 (high/intermediate/low), n | 24/15/1 |
| First-line therapy, n | |
| Prednisone (alone or with other drugs) | 36 |
| Miscellaneous (including MMF, tacrolimus, ECP, CSA) | 4 |
| Second and successive lines of therapy, n | |
| Rituximab + miscellaneous (no ECP) | 5 |
| Rituximab + ECP ± miscellaneous | 8 |
| Miscellaneous, including ECP (no rituximab) | 8 |
| Miscellaneous, excluding ECP and rituximab | 19 |
| Karnofsky performance status at enrollment, n (%) | |
| <70 | 28 (70%) |
| 80 | 9 (22%) |
| 90–100 | 3 (8%) |
| Platelet count before imatinib initiation, 109/L, n (%) | |
| <100 | 2 (5%) |
| >100 | 38 (95%) |
| Main cGVHD targets (different organ involvements are not mutually exclusive) | |
| Skin, n (%) | 32 (80%) |
| Mean affected BSA% for erythematous/moveable/nonmoveable sclerosis | 19/27/27 |
| Lung, n (%) | 33 (82.5%) |
| Median values of FEV1/DLCO | 61/55 |
| Mouth, n (%) | 23 (57.5%) |
| Median Schubert Scale value | 3 |
| Liver, n (%) | 6 (15%) |
| Median values of ALT (U/L)/total bilirubin (mg/dL) | 74/3.0 |
| Gut, n (%) | 9 (22.5%) |
| Mean value of the GI scale (0-3) | 1.5 |
ALT, alanine transaminase; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CSA, cyclosporine; HD, Hodgkin disease; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; MMF, mycophenolate mofetil; MUD, matched unrelated donor; NHL, non-Hodgkin lymphoma; and PBSC, peripheral blood stem cells.